• A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages
• Bi-allelic variants in the ESAM tight-junction gene cause a neurodevelopmental disorder associated with fetal intracranial hemorrhage
• BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis
• Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature
• Characterization of myeloproliferative neoplasms in the paediatric and young adult population
• Chronic Myeloproliferative Neoplasms Treatment (PDQ®): Patient Version
• Familial myelofibrosis
• First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis
• Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
• Primary Hypertrophic Osteoarthropathy With Myelofibrosis
• Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis
• Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
• Recent knowledge of NFATc4 in oncogenesis and cancer prognosis
• The emerging importance of immunophilins in fibrosis development
• The Outcome of Fatherhood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms: A Single-Institution Experience
• The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms
• Treatment of congenital thrombocytopenia and decreased collagen reactivity in G6b-B-deficient mice